ロード中...
An osteopontin/CD44 immune checkpoint controls CD8(+) T cell activation and tumor immune evasion
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune chec...
保存先:
| 出版年: | J Clin Invest |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Clinical Investigation
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6264631/ https://ncbi.nlm.nih.gov/pubmed/30395540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123360 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|